TG Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $141.15 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.75$73.47 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on manageme ...